Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
Crossref DOI link: https://doi.org/10.1007/s10637-014-0141-2
Published Online: 2014-08-01
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Grabinski, Nicole
Ewald, Florian
Text and Data Mining valid from 2014-08-01
Version of Record valid from 2014-08-01
Article History
Received: 6 June 2014
Accepted: 21 July 2014
First Online: 1 August 2014